IRIS
IAFFALDANO, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.508
AS - Asia 2.694
EU - Europa 2.532
SA - Sud America 672
Continente sconosciuto - Info sul continente non disponibili 461
AF - Africa 221
OC - Oceania 10
Totale 13.098
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.349
SG - Singapore 1.009
IT - Italia 924
CN - Cina 602
BR - Brasile 495
SE - Svezia 351
RU - Federazione Russa 326
HK - Hong Kong 324
VN - Vietnam 217
GB - Regno Unito 191
DE - Germania 183
FR - Francia 174
BD - Bangladesh 116
CI - Costa d'Avorio 114
FI - Finlandia 109
IN - India 81
CA - Canada 78
AR - Argentina 77
NL - Olanda 58
JP - Giappone 49
IQ - Iraq 44
UA - Ucraina 41
ID - Indonesia 38
MX - Messico 36
SA - Arabia Saudita 35
BE - Belgio 33
ZA - Sudafrica 27
EC - Ecuador 26
PL - Polonia 26
CO - Colombia 25
PK - Pakistan 25
TR - Turchia 25
PH - Filippine 23
UZ - Uzbekistan 23
AT - Austria 21
ES - Italia 21
VE - Venezuela 21
TN - Tunisia 15
EG - Egitto 13
JM - Giamaica 12
JO - Giordania 11
KE - Kenya 11
LT - Lituania 11
CL - Cile 10
AE - Emirati Arabi Uniti 9
CR - Costa Rica 9
MA - Marocco 9
MY - Malesia 9
AU - Australia 8
CZ - Repubblica Ceca 8
IL - Israele 8
IE - Irlanda 7
PY - Paraguay 7
ET - Etiopia 6
IR - Iran 6
NP - Nepal 6
PT - Portogallo 6
RO - Romania 6
AL - Albania 5
SN - Senegal 5
UY - Uruguay 5
BB - Barbados 4
BO - Bolivia 4
CH - Svizzera 4
DK - Danimarca 4
DZ - Algeria 4
EE - Estonia 4
GT - Guatemala 4
HU - Ungheria 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LB - Libano 4
PS - Palestinian Territory 4
AZ - Azerbaigian 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
EU - Europa 3
LV - Lettonia 3
MZ - Mozambico 3
OM - Oman 3
PA - Panama 3
A1 - Anonimo 2
HN - Honduras 2
MK - Macedonia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
RW - Ruanda 2
SV - El Salvador 2
TH - Thailandia 2
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
BJ - Benin 1
BT - Bhutan 1
BY - Bielorussia 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
Totale 12.618
Salva come PNG Salva come JPEG
Città #
Ashburn 718
Fairfield 616
Singapore 511
Chandler 432
Woodbridge 378
San Jose 347
Dallas 324
Hong Kong 324
Milan 282
Houston 280
Nyköping 270
Seattle 256
Ann Arbor 240
Cambridge 212
Beijing 180
Wilmington 176
Council Bluffs 157
Los Angeles 117
Abidjan 114
New York 101
Lauterbourg 99
Lawrence 81
Jacksonville 77
Roxbury 71
Bari 70
Helsinki 69
Ho Chi Minh City 69
Rome 69
Boardman 64
Brooklyn 56
Columbus 55
São Paulo 54
Santa Clara 53
Buffalo 49
Des Moines 49
Chicago 48
Tokyo 44
Munich 42
Hanoi 41
Nanjing 41
London 37
Princeton 37
Moscow 36
Frankfurt am Main 35
Brussels 33
Amsterdam 32
Falkenstein 31
Nuremberg 31
Orem 31
Inglewood 30
Toronto 30
San Diego 27
Guangzhou 26
North Bergen 26
Figino 23
Jakarta 20
Norwalk 20
Paris 20
Atlanta 18
Rio de Janeiro 18
Salt Lake City 18
Warsaw 18
Montreal 17
Shanghai 17
Jeddah 16
Johannesburg 16
Baghdad 15
Phoenix 15
Poplar 15
San Francisco 15
Turin 15
Naples 14
Tashkent 14
Dong Ket 13
Stockholm 13
Tianjin 13
Denver 12
Dhaka 12
Quito 12
Bisceglie 11
Buenos Aires 11
Chennai 11
Haiphong 11
Lahore 11
Shenyang 11
Taranto 11
Amman 10
Bologna 10
Cagliari 10
Manchester 10
Nanchang 10
Washington 10
Boston 9
Da Nang 9
Dearborn 9
Medellín 9
Miami 9
Nairobi 9
Vienna 9
Belo Horizonte 8
Totale 8.285
Salva come PNG Salva come JPEG
Nome #
Signs and symptoms of COVID-19 in patients with multiple sclerosis 224
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 219
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 214
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 208
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 198
Computer-assisted rehabilitation of attention in pediatric multiple sclerosis and ADHD patients: a pilot trial 197
Prognostic indicators in pediatric clinically isolated syndrome 192
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 187
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 185
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 184
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 180
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 175
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 171
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 163
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 162
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 158
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 155
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 155
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 151
Treatment decisions in multiple sclerosis-insights from real-world observational studies 148
Multiple sclerosis registries in Europe – An updated mapping survey 145
Sclerosi Multipla e Lavoro: dati preliminari 145
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 144
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 142
Multiple Sclerosis Progression and Relapse Activity in Children 141
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 140
Treating multiple sclerosis with natalizumab. 135
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 135
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 130
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 129
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 129
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis 128
Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis 127
Detection of disability worsening in relapsing-remitting multiple sclerosis patients. A real-world roving EDSS-Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register 124
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 124
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 124
Safety profile of Tysabri: international risk management plan 123
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 123
Geographical variations in sex ratio trends over time in multiple sclerosis. 123
Emotional and neutral verbal memory impairment in Multiple Sclerosis 123
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 123
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 122
The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. 122
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 122
Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients 121
Low serum urate levels are associated to female gender in multiple sclerosis patients. 120
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 120
Dengue fever in a multiple sclerosis patient taking Ocrelizumab 119
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica 118
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 118
Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients 117
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 116
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 116
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study 114
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 113
A Randomized Computer-Assisted Rehabilitation Trial of Attention in Pediatric Multiple Sclerosis: A Post Hoc Analysis 112
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register 111
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 111
Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing 110
Disability assessment using Google Maps 110
Predictors and dynamics of postpartum relapses in women with multiple sclerosis. 109
null 109
First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients 109
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 108
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 107
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries 102
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 102
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patients 100
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network 99
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis 98
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 97
Anxiety state affects information processing speed in patients with multiple sclerosis 96
Age-dependent response to initial highly effective treatment in relapsing multiple sclerosis 92
Assessing long-term effectiveness of MS treatment - a matter of debate 91
Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis 89
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 87
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study 87
Natalizumab reduces serum pro-angiogenic activity in MS patients 86
Big Multiple Sclerosis Data network: an international registry research network 84
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study 84
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network 84
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA) 82
The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study. 81
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis 79
Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate 78
Serum N-acetyl-aspartate in Relapsing Remitting Multiple Sclerosis 77
Risk of Getting COVID-19 in People With Multiple Sclerosis 77
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 76
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 74
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 74
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register 74
null 73
Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series 72
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 71
Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry 69
null 68
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 67
null 67
null 65
Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender 65
Totale 12.004
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.095
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.095
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022621 0 0 21 23 49 87 34 44 51 48 117 147
2022/20231.102 158 170 88 87 128 131 20 120 151 4 26 19
2023/2024442 41 54 29 24 41 95 16 25 6 30 11 70
2024/20252.094 149 38 126 74 68 153 223 187 126 116 291 543
2025/20265.336 653 362 478 473 540 381 447 192 545 506 182 577
2026/2027522 184 216 122 0 0 0 0 0 0 0 0 0
Totale 13.098